Oxford Biomedica

Next week, our CEO, Dr. Frank Mathias, CFO, Lucinda (Lucy) Crabtree, PhD and Head of Investor Relations, Sophia Bolhassan, will be at the Jefferies London Healthcare Conference. If you are at the conference, please join us for Frank’s presentation on Tuesday 19th November at 10:00am UK time, where he will share the progress we have made on our transformation to a pure-play cell and gene therapy CDMO. If you’d like to connect with us at the conference, please reach out to Sophia Bolhassan directly. #JefferiesHealthcare #OXB #CellAndGeneTherapy #CDMO

Yesterday, our CFO, Lucinda Crabtree, PhD, joined the panel discussion on "Can pension funds fuel the growth of the life sciences in the UK". This forum, hosted by 5654 & Company, LSEG (London Stock Exchange Group), Citi, Peel Hunt, and Covington & Burling LLP, addressed the impact of the Mansion House Compact and key issues facing the UK life sciences industry.   The panel explored how companies, investors, and the government can work together to drive growth in this innovative sector. Thank you to everyone who contributed to this important conversation!   #LifeSciences #Innovation #OXB #Growth #CDMO

At European Society of Gene and Cell Therapy (ESGCT) this year, we’re proud to highlight Emma Whiteley's poster on our innovative TetraVecta™ packaging cell lines for lentiviral vector (LV)-CAR production. The PaC-TeTRA cell line leverages our unique TRiP System™, which effectively represses transgene expression in production cells. This allows for high-quality, high-yield production of LV-CAR constructs and ultimately enables us to better support our clients' needs for complex gene therapy solutions.   Key advancements include: 🔹 Inducible LV production 🔹 Enhanced output with the TRiP system™ 🔹 Optimised productivity 🔗 Explore Emma's poster here: https://lnkd.in/exTPiFMS   #ESGCT2024 #GeneTherapy #CellTherapy #CellAndGeneTherapy #LentiviralVectors #ViralVectors #TetraVecta #CDMO #GMP #Innovation

In our latest video, André Raposo shares how our 4th generation lentiviral vector (the TetraVecta™ system) and high-titre stable producer cell lines (the LentiStable™ technology) are setting new standards for quality and efficiency for gene therapy. Andre also sheds light on our digital transformation and DoE services which are powered by automated systems. Curious to learn more? Watch the full video to see how we’re shaping the future of cell and gene therapy with cutting-edge innovation and reach out to us at partnering@oxb.com if you’d like to learn more. #CellAndGeneTherapy #Innovation #LentiviralVectors #DigitalTransformation #CDMO #ProducerCellLines #ViralVectors

In our latest blog, André Raposo, Director of the Computer-aided Biology and Platform Proteomics Groups at OXB, shares insights into how his team are leveraging advanced technologies to improve therapeutic development. Andre shares how his team’s breakthroughs in automation, high-throughput analytics, and innovations like the TetraVecta™ system and our LentiStable™ technology are accelerating therapeutic development and improving client outcomes. Join our upcoming webinar on December 9 at 16:00 GMT/17:00 CET to learn how advanced automation and digital platforms can reshape the future of gene therapy. Click here to register: https://lnkd.in/eDW8GYu5 #CDMO #ViralVectors #Automation #Analytics #CellAndGeneTherapy #Innovation #AdvancedTherapies #Webinar

We are excited to share that our CFO, Lucinda Crabtree, will be joining a panel discussion at the upcoming Mansion House Compact on November 13. Lucy will participate in an insightful discussion alongside: 🔹 Chris Eccles, Fund Manager at AXA 🔹 Chris Hollowood, CEO at Syncona 🔹 Michael Stiasny, Head of UK Equities at M&G 🔹 Tim Davis, Regional Head of UK Equity at LSE Together, they’ll explore whether the Mansion House Compact can be a catalyst for revitalising the life sciences public markets. #MansionHouseCompact #LifeSciences #Investment #Innovation #PublicMarkets

Next week, we will be attending Advanced Therapies USA 2024 in Philadelphia! If you’d like to connect with us at the conference, please reach out to Konstantin from our Business Development team or meet him during one of his poster sessions. Poster session details: ▪️ November 12 | 10:45 - 11:30 AM ▪️ November 13 | 10:25 - 11:10 AM #AdvancedTherapiesUSA2024 #Conference #CDMO #ViralVectors #CellAndGeneTherapy #AdvancedTherapies #AAV #Lentivirus #Biotechnology

We’re exhibiting at Cell 2024 next week in London and we’d love to connect! If you’re interested in discussing your viral vector development and manufacturing needs with us, please stop by our booth or reach out to us at partnering@oxb.com to schedule a meeting. Don't miss the opportunity to listen to André Raposo, a Director in our Department of Innovation, present at the conference on 7th November in Track 3 on two key advancements in lentiviral vector production. #BIOEurope #Cell2024 #Conferences #ViralVectors #CDMO #GeneTherapy #Partnering #OXB #Biotech

The tech transfer of our LentiVector™ platform to our Bedford site is a cornerstone of our multi-vector, multi-site model that spans the UK, US and EU. In this video, John Maravich, Site Head of US Operations, delves into the core strategies involved in the tech transfer process, and shares how his team collaborates across our global site network to ensure the highest standards of consistency and quality for our viral vectors. This tech transfer underscores our commitment to be able to offer our clients the flexibility to access all our viral vector CDMO services across our multi-site network. Please email us at partnering@oxb.com if you’d like to learn more. #CDMO #ViralVectors #CellAndGeneTherapy #Innovation #GlobalOperations #OXB #Leadership #Collaboration #TechTransfer 

Meet Stéphanie COLLOUD, Site Head and General Manager of France Operations at OXB! In this video, Stephanie highlights the pivotal role our French sites in Lyon and Strasbourg play in enabling us to support our clients deliver their life-changing therapies to patients. She shares how these locations are driving innovation and collaboration within the global OXB network and the strategic importance of expanding our capabilities into the EU. Watch now to see how our operations in France are ensuring we meet growing client demand for our CDMO services. #CDMO #ViralVectors #CellAndGeneTherapy #Innovation #GlobalOperations #EUExpansion #OXB #Leadership #Collaboration #Innovation #OXB